NCT05003531

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

A Phase II Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 administered in different dose regimens for the treatment of patients with plaque psoriasis

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	IBI112 dose 2	Participants will receive placebo or dose 2 IBI112 SC
DRUG	IBI112 dose 4	Participants will receive placebo or dose 4 IBI112 SC
DRUG	IBI112 dose 1	Participants will receive placebo or dose 1 IBI112 SC
DRUG	IBI112 dose 3	Participants will receive placebo or dose 3 IBI112 SC
DRUG	placebo	Participants will receive placebo SC

Timeline

• Start date: 2021-09-23
• Primary completion: 2022-03-25
• Completion: 2023-01-17
• First posted: 2021-08-12
• Last updated: 2024-01-25

Locations

1 site across 1 country: China